Published in J Psychiatry Neurosci on May 01, 2004
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci (2004) 1.61
Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J Psychiatry Neurosci (2004) 1.61
Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci (2004) 1.46
Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci (2004) 1.39
Implications of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci (2004) 1.24
Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression. J Psychiatry Neurosci (2004) 1.15
Glutamate co-transmission as an emerging concept in monoamine neuron function. J Psychiatry Neurosci (2004) 1.09
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci (2004) 0.90
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes. J Psychiatry Neurosci (2004) 0.88
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2007) 3.22
Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. Nat Biotechnol (2002) 2.87
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry (2007) 2.13
From glutamate co-release to vesicular synergy: vesicular glutamate transporters. Nat Rev Neurosci (2011) 1.79
The dual dopamine-glutamate phenotype of growing mesencephalic neurons regresses in mature rat brain. J Comp Neurol (2009) 1.55
The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res (2005) 1.55
Dopamine neurons in culture express VGLUT2 explaining their capacity to release glutamate at synapses in addition to dopamine. J Neurochem (2004) 1.52
Preserved awareness of their cognitive deficits in patients with schizophrenia: convergent validity of the SSTICS. Schizophr Res (2008) 1.48
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf (2012) 1.42
Developmental and target-dependent regulation of vesicular glutamate transporter expression by dopamine neurons. J Neurosci (2008) 1.39
Glutamate in dopamine neurons: synaptic versus diffuse transmission. Brain Res Rev (2007) 1.39
Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr Bull (2004) 1.31
VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. Proc Natl Acad Sci U S A (2009) 1.21
The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci (2006) 1.10
Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis. Can J Psychiatry (2008) 1.09
Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res (2004) 1.07
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry (2011) 1.06
Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res (2008) 1.06
Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res (2005) 1.04
Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res (2004) 1.04
Presynaptic mu-opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons. Neuropharmacology (2002) 1.02
D2 receptors inhibit the secretory process downstream from calcium influx in dopaminergic neurons: implication of K+ channels. J Neurophysiol (2002) 1.02
Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case study. J Psychiatry Neurosci (2002) 1.01
Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry (2007) 1.01
CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn (2005) 1.00
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
Predictors of quality of life in schizophrenia. Community Ment Health J (2005) 1.00
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia (2011) 0.99
Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res (2007) 0.98
Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr Res (2003) 0.98
Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study. Schizophr Res (2009) 0.97
Culture of postnatal mesencephalic dopamine neurons on an astrocyte monolayer. Curr Protoc Neurosci (2008) 0.95
Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. Eur Arch Psychiatry Clin Neurosci (2014) 0.95
Basal somatodendritic dopamine release requires snare proteins. J Neurochem (2006) 0.94
The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry (2004) 0.94
Nestin-expressing neural stem cells identified in the scar following myocardial infarction. J Cell Physiol (2005) 0.94
Contribution of Kv1.2 voltage-gated potassium channel to D2 autoreceptor regulation of axonal dopamine overflow. J Biol Chem (2011) 0.94
Ultrastructural characterization of the mesostriatal dopamine innervation in mice, including two mouse lines of conditional VGLUT2 knockout in dopamine neurons. Eur J Neurosci (2012) 0.93
Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf (2008) 0.93
Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res (2005) 0.92
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) (2003) 0.92
Coordinated action of NSF and PKC regulates GABAB receptor signaling efficacy. EMBO J (2006) 0.91
Somatodendritic dopamine release requires synaptotagmin 4 and 7 and the participation of voltage-gated calcium channels. J Biol Chem (2011) 0.91
Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J Neurosci (2004) 0.90
Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. J Psychiatr Res (2008) 0.90
ERP investigation of study-test background mismatch during face recognition in schizophrenia. Schizophr Res (2011) 0.89
Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology (2006) 0.89
Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin (2007) 0.89
Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Expert Rev Neurother (2011) 0.89
Pain perception in schizophrenia: evidence of a specific pain response profile. Pain Med (2012) 0.88
Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol (2011) 0.88
Treating delusional disorder: a comparison of cognitive-behavioural therapy and attention placebo control. Can J Psychiatry (2007) 0.88
Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol (2007) 0.88
Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function. BMC Neurosci (2009) 0.87
Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychopharmacol (2005) 0.87
Chronic exposure to nerve growth factor increases acetylcholine and glutamate release from cholinergic neurons of the rat medial septum and diagonal band of Broca via mechanisms mediated by p75NTR. J Neurosci (2008) 0.87
Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology (2006) 0.87
Agenesis of corpus callosum and emotional information processing in schizophrenia. Front Psychiatry (2012) 0.87
Neural correlates of emotional recognition memory in schizophrenia: effects of valence and arousal. Psychiatry Res (2011) 0.87
Sleep habits in middle-aged, non-hospitalized men and women with schizophrenia: a comparison with healthy controls. Psychiatry Res (2010) 0.87
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses (2013) 0.86
Role of Kv1 potassium channels in regulating dopamine release and presynaptic D2 receptor function. PLoS One (2011) 0.86
Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists. Cell Mol Life Sci (2014) 0.86
The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice. Eur J Neurosci (2011) 0.85
Attention and non-REM sleep in neuroleptic-naive persons with schizophrenia and control participants. Psychiatry Res (2006) 0.85
Daily activities, cognition and community functioning in persons with schizophrenia. Schizophr Res (2008) 0.85
Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res (2009) 0.85
Impact of basic FGF expression in astrocytes on dopamine neuron synaptic function and development. Eur J Neurosci (2006) 0.85
Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res (2012) 0.85
A study of theory of mind in paranoid schizophrenia: a theory or many theories? Front Psychol (2012) 0.85
Use of the process dissociation procedure to study the contextual effects on face recognition in schizophrenia: familiarity, associative recollection and discriminative recollection. Psychiatry Res (2006) 0.84
The incidence and nature of cerebellar findings in schizophrenia: a quantitative review of fMRI literature. Schizophr Bull (2012) 0.84
The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res (2004) 0.84
Memory and executive functions in adults with Gilles de la Tourette syndrome and chronic tic disorder. Cogn Neuropsychiatry (2007) 0.84
Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol (2008) 0.84
Do patients with schizophrenia attribute mental states in a referential communication task? Cogn Neuropsychiatry (2009) 0.84
Relationship between psychotic and obsessive compulsive symptoms in schizophrenia. Schizophr Res (2009) 0.84
NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease. Nanomedicine (2012) 0.83
Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice. Mol Biol Cell (2004) 0.83
Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. Neuropharmacology (2012) 0.83
Blockade of mGLUR5 receptors differentially alters amphetamine-induced enhancement of locomotor activity and of brain stimulation reward. J Psychopharmacol (2010) 0.83
Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. J Neuropsychiatry Clin Neurosci (2003) 0.83
Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study. Soc Neurosci (2007) 0.83
Electrophysiological manifestations of stimulus evaluation, response inhibition and motor processing in Tourette syndrome patients. Psychiatry Res (2009) 0.82
Postsynaptic injection of calcium-independent phospholipase A2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission. Hippocampus (2004) 0.82
Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments. Cogn Behav Neurol (2004) 0.82
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophr Res (2005) 0.82
Sex differences in the cerebral function associated with processing of aversive stimuli by schizophrenia patients. Aust N Z J Psychiatry (2007) 0.82
Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol (2010) 0.82
Genealogy of instruments for prodrome evaluation of psychosis. Front Psychiatry (2013) 0.82
[The role of social support, family burden and satisfaction with services in psychological distress and quality of life of families of individuals with schizophrenia]. Sante Ment Que (2005) 0.82
Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord (2010) 0.81
M3-like muscarinic receptors mediate Ca2+ influx in rat mesencephalic GABAergic neurones through a protein kinase C-dependent mechanism. Neuropharmacology (2005) 0.81
Blockade of ventral midbrain NMDA receptors enhances brain stimulation reward: a preferential role for GluN2A subunits. Eur Neuropsychopharmacol (2013) 0.81
Language functions in right-hemisphere damage and schizophrenia: apparently similar pragmatic deficits may hide profound differences. Brain (2007) 0.81